United States Drug Manufacturers - General news

00:09 19 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Amarin to release Q2 results before July 29 conference call

Amarin (NASDAQ: AMRN) announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before market open. This will be followed by a conference call with senior management at 8:00 a.m. ET. Investors can access the live call via telephone …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

00:09 19 Jul 2026

Intellectia AI Guidance Main company 🇺🇸 United States

GRFS Technical Analysis & Stock Price Forecast

The technical analysis for Grifols SA (GRFS) indicates a "Sell" consensus, driven by various indicators. While some moving averages show "Buy" signals, the MACD, longer-term moving averages, and the overall aggregated signals point towards a bearish outlook. Key support is identified at $7.015 and …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

23:25 18 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Gilead Stock Tops 3 GARP Picks Trading On More Measured Valuations

This article highlights three Growth at a Reasonable Price (GARP) stocks—Belden (BDC), Daktronics (DAKT), and Gilead Sciences (GILD)—that offer solid fundamentals and appear reasonably valued compared to the current AI-driven market trends. It discusses their revenue streams, market caps, and potential risks, suggesting they …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

22:07 18 Jul 2026

Quartr Deals and strategy Main company 🇺🇸 United States

Bristol-Myers Squibb Company (BMY) Q2 2024 earnings summary

Bristol-Myers Squibb (BMY) reported strong Q2 2024 results with revenues up 9% to $12.2B, driven by its Growth Portfolio, despite Revlimid declines. The company achieved several regulatory approvals and completed major acquisitions, expanding its pipeline. BMY also launched a $1.5B cost-saving initiative and raised …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

21:37 18 Jul 2026

Quartr Earnings Main company 🇺🇸 United States

Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Bristol-Myers Squibb (BMY) aims for sustained top-tier growth by focusing on transformational medicines, operational excellence, and disciplined capital allocation, having achieved double-digit revenue growth in 2024. The company highlights five key growth products and anticipates next-wave assets like the CELMoD platform and Milvexian to …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

17:51 18 Jul 2026

The Globe and Mail Earnings Main company 🇺🇸 United States

Eli Lilly & Co (LLY) Gets a Hold from Berenberg Bank

Berenberg Bank analyst Harry Gillis maintained a Hold rating on Eli Lilly & Co (LLY) with a price target of $1,135.00. The article notes Eli Lilly's strong financial performance, reporting $19.8 billion in quarterly revenue and $7.4 billion in net profit, significantly higher than …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

15:58 18 Jul 2026

ad-hoc-news.de Earnings Main company 🇺🇸 United States

The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges including cold chain requirements, and its safety profile based …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

13:41 18 Jul 2026

McDermott Will & Schulte Market update Provider-linked mention 🇺🇸 United States

Mylan Beats Sanofi Appeal in Insulinpen Patent Fight

Mylan has successfully beaten an appeal from Sanofi in their ongoing patent dispute regarding the Insulinpen. The article is a brief news item from McDermott Will & Schulte, likely highlighting a legal victory for one of their clients or a related legal matter. The …

SNY mentioned

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

10:55 18 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

John G Ullman & Associates Inc. Sells 6,675 Shares of Amgen Inc. $AMGN

John G Ullman & Associates Inc. significantly reduced its stake in Amgen Inc. in the first quarter of 2026, selling 6,675 shares and decreasing its position by 75.9%. Despite this, other institutional investors have increased their holdings. Amgen's stock maintains a "Hold" rating from …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

10:34 18 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Illinois Municipal Retirement Fund Has $5.38 Million Position in Amgen Inc. $AMGN

The Illinois Municipal Retirement Fund significantly increased its stake in Amgen Inc. by 68.8% in the first quarter, now holding 15,295 shares valued at $5.38 million. Other institutional investors also adjusted their positions in Amgen, with several analysts offering new price targets and ratings. …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

10:26 18 Jul 2026

ad-hoc-news.de Earnings Main company 🇺🇸 United States

Grifols stock holds focus as 2025 results frame the next move

Grifols stock remains focused on its 2025 financial reporting, with revenue, EBITDA, and cash flow being key metrics guiding investor perception of the Spanish plasma group. The article emphasizes that the company's valuation is driven by its plasma network's scale, collection pace, and conversion …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

09:53 18 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Amgen Inc. $AMGN Stock Position Lowered by California Public Employees Retirement System

The California Public Employees Retirement System reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 5.6% in the first quarter, selling 116,919 shares. Despite this, other major institutional investors like Vanguard Group Inc., State Street Corp, and Capital World Investors increased their holdings in Amgen. …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

09:15 18 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Amgen Inc. $AMGN Holdings Decreased by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC has reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 5.2% in the first quarter, selling 18,221 shares and now owning 329,953 shares valued at $106.86 million. Despite this decrease, Amgen remains a significant holding for the firm, comprising …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

08:55 18 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Atlas Wealth LLC Has $25.50 Million Position in Amgen Inc. $AMGN

Atlas Wealth LLC significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) by 11,152.0% in the first quarter, now holding 72,463 shares valued at $25.50 million, making it their 9th largest position. Other hedge funds also adjusted their holdings, while Amgen saw mixed sentiment from …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

08:53 18 Jul 2026

ETPharma.com Market update Main company 🇺🇸 United States

Novo Nordisk to launch lower-cost Ozempic copy in South Africa

Novo Nordisk is set to launch a more affordable, authorised copy of its Ozempic diabetes drug, named Extensior, in South Africa on July 27th. This move, in partnership with healthcare company Acino, aims to increase patient access to semaglutide, the active ingredient in Ozempic, …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

06:43 18 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research

This article identifies three AI healthcare stocks—Pfizer (PFE), Tempus AI (TEM), and Medtronic (MDT)—as compelling for further research, given the growing importance of AI in diagnostics, treatment, and efficiency within the healthcare sector. It highlights their individual strengths, such as Pfizer's broad portfolio and …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

06:22 18 Jul 2026

ad-hoc-news.de Earnings Main company 🇺🇸 United States

Merck stock steadies as Keytruda drives double digit growth

Merck & Co. (US58933Y1055) stock continues to be driven by the strong performance of its oncology drug Keytruda, which contributes double-digit revenue growth and maintains a central role in large-cap healthcare portfolios. The company's strategy focuses on balancing Keytruda's growth, managing upcoming patent expiries, …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

06:10 18 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Amarin (AMRN) CFO acquires 2,447 ADS; 1,206 withheld for taxes

Amarin Corporation's SVP & CFO, Peter L. Fishman, acquired 2,447 American Depositary Shares (ADS) on July 1, 2026, through an equity award vesting from the 2020 Stock Incentive Plan. The company withheld 1,206 ADS at $15.94 per ADS to cover taxes, which was not …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

05:46 18 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Amgen (AMGN) Earnings Buzz Builds, Is The Stock Already Overvalued?

Amgen (AMGN) is garnering investor attention due to a string of recent earnings surprises and its stock performance, which has seen a 7.21% gain over the past month and 11.80% year-to-date. While analysts frequently point to a fair value estimate of $352, suggesting the …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

01:11 18 Jul 2026

AllSci Deals and strategy Main company 🇺🇸 United States

Aqemia Expands Sanofi AI Drug Discovery Deal

Aqemia and Sanofi have expanded their multi-year drug discovery collaboration, with Aqemia announcing a new therapeutic target nomination. This expansion makes Aqemia eligible for up to $140 million in aggregate payments. The partnership utilizes Aqemia's physics-based generative AI platform, Qemi, to design molecules for …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

23:00 17 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of 1.01%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%. Shares of the HIV and hepatitis C drugmaker …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

20:41 17 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

GSK (GSK) Stock Price, News & Analysis $GSK

GSK (GlaxoSmithKline plc) is a London-headquartered pharmaceutical company focused on prescription medicines, vaccines, and specialty treatments. The company's stock currently has a "Hold" consensus rating from analysts, with a price target of $53.00, approximately 5.5% higher than its current trading price. Recent news indicates …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

20:40 17 Jul 2026

Stock Titan Deals and strategy Main company 🇺🇸 United States

[8-K] Organon & Co. Reports Material Event

Organon & Co. has filed an 8-K report providing supplemental disclosures related to its proposed merger with Sun Pharma, which is scheduled for a stockholder vote on July 23, 2026. The disclosures include approximately $700 million in potential synergies, unaudited financial projections through 2030, …

OGN main company

Sharemaestro market context Trend signal active 52 weeks +46.5%

20:40 17 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

GSK plc (NYSE: GSK) plans Deloitte re-appointment as external auditor from 2028

GSK plc announced its decision to re-appoint Deloitte LLP as its external auditor starting from the financial year ending December 31, 2028, following a competitive tender process. As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

20:09 17 Jul 2026

Market source Earnings Main company 🇺🇸 United States

AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe

AbbVie's Allergan Aesthetics has received European Commission approval for Boey (trenibotulinumtoxinE), a new rapid-onset neurotoxin for treating frown lines. This product aims to expand AbbVie's aesthetics portfolio in Europe by offering patients faster visible effects and more flexible treatment schedules. Investors are encouraged to …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

19:10 17 Jul 2026

Market source Regulatory and legal Main company 🇺🇸 United States

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

Novartis recently received traditional FDA approval for Fabhalta (iptacopan) to treat primary IgA nephropathy, converting its prior accelerated approval. This approval is based on strong clinical trial data showing Fabhalta slows kidney function decline, reinforcing Novartis's growing nephrology portfolio which also includes Vanrafia and …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

18:39 17 Jul 2026

Morningstar Earnings Main company 🇺🇸 United States

Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk

Novo Nordisk received EU approval for its Wegovy pill, expanding its market opportunity, particularly through cash-pay sales in Europe, the US, and UAE. Despite increasing the 2030 sales forecast for the Wegovy pill to $11 billion, Morningstar lowered Novo Nordisk's fair value estimate to …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:29 17 Jul 2026

Seeking Alpha Earnings Main company 🇺🇸 United States

Novo Nordisk: The Oral Wegovy Promise (NYSE:NVO)

Novo Nordisk has received EU approval for its oral Wegovy pill for weight management, marking the first GLP-1 receptor agonist in pill form cleared for this use in the region. This approval strengthens the company's obesity portfolio and offers patients an alternative to injectable …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:10 17 Jul 2026

The National Law Review Regulatory and legal Main company 🇺🇸 United States

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AstraZeneca PLC (AZN) after its late-stage Phase-3 CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to meet its primary endpoint, causing a significant drop in the company's American Depositary Share (ADS) price. The …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks -1.4%

18:04 17 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5. Continue Reading

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

17:40 17 Jul 2026

Investor's Business Daily Deals and strategy Main company 🇺🇸 United States

Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.

Personalis (PSNL) stock initially surged before reversing lower following rumors that Merck (MRK) and at least two other companies, including Tempus AI (TEM), are attempting to acquire the genomics firm. Both Merck and Tempus AI currently hold stakes in Personalis. This development highlights potential …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

17:10 17 Jul 2026

Benzinga Regulatory and legal Main company 🇺🇸 United States

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

The FDA has granted full approval to Novartis's oral medication Fabhalta (iptacopan) to slow kidney function decline in adult patients with primary immunoglobulin A nephropathy (IgAN). This treatment could delay the need for dialysis or transplant for at-risk individuals. The decision was based on …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:10 17 Jul 2026

Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

Novartis wins full FDA approval for kidney disease drug Fabhalta in IgA nephropathy

Novartis has received full FDA approval for its kidney disease drug Fabhalta (iptacopan), specifically for primary immunoglobulin A nephropathy, also known as Berger disease. Fabhalta is an oral Factor B inhibitor designed to treat this autoimmune condition. This approval marks a significant step for …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:10 17 Jul 2026

Intellectia AI Earnings Main company 🇺🇸 United States

Novartis Receives Full FDA Approval for Kidney Disease Therapy

Novartis has received full FDA approval for its kidney disease therapy, Fabhalta (iptacopan), for treating primary immunoglobulin A nephropathy (IgAN). Clinical trials showed significant improvement in estimated glomerular filtration rate over two years, solidifying its efficacy in slowing kidney function decline. This approval, coupled …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:00 17 Jul 2026

Medical Marketing and Media Market update Main company 🇺🇸 United States

With Up To Date campaign, Gilead brings HIV prevention into the dating conversation

Gilead Sciences has launched its "Up To Date" campaign, featuring comedians Nicole Byer and Devon Walker, to normalize conversations around HIV prevention, testing, and PrEP, particularly targeting Black women. The campaign uses humor and culturally relevant media placements like streaming services, social media, and …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

16:48 17 Jul 2026

finance.yahoo.com Analyst action Main company 🇺🇸 United States

Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%